Literature DB >> 3262228

Breast cancer: PET imaging of estrogen receptors.

M A Mintun1, M J Welch, B A Siegel, C J Mathias, J W Brodack, A H McGuire, J A Katzenellenbogen.   

Abstract

Thirteen patients with primary breast masses were studied with positron emission tomography (PET) and 16 alpha-[fluorine-18]-fluoroestradiol-17 beta. PET images demonstrated uptake of the labeled estrogen analog at sites of primary carcinomas and in several foci of axillary lymph node metastases, as well as in one distant metastatic site. There was excellent correlation between uptake within the primary tumor measured on the PET images and the tumor estrogen-receptor concentration measured in vitro after excision (r = .96). This technique may provide an in vivo method of assessing estrogen receptors in primary and metastatic breast cancers and thus guide management of this disease with antiestrogen chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262228     DOI: 10.1148/radiology.169.1.3262228

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  71 in total

1.  Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.

Authors:  Amy M Fowler; Szeman Ruby Chan; Terry L Sharp; Nicole M Fettig; Dong Zhou; Carmen S Dence; Kathryn E Carlson; M Jeyakumar; John A Katzenellenbogen; Robert D Schreiber; Michael J Welch
Journal:  J Nucl Med       Date:  2012-06-05       Impact factor: 10.057

Review 2.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

Authors:  D A Mankoff; F Dehdashti; A F Shields
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 3.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

4.  Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.

Authors:  Nina Mortazavi-Jehanno; Anne-Laure Giraudet; Laurence Champion; Florence Lerebours; Elise Le Stanc; Veronique Edeline; Olivier Madar; Dominique Bellet; Alain Paul Pecking; Jean-Louis Alberini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-20       Impact factor: 9.236

Review 5.  [Molecular imaging with new PET tracers].

Authors:  A J Beer; M Schwaiger
Journal:  Radiologe       Date:  2007-01       Impact factor: 0.635

Review 6.  Current and future use of positron emission tomography (PET) in breast cancer.

Authors:  David A Mankoff; William B Eubank
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-04       Impact factor: 2.673

Review 7.  Targeted functional imaging in breast cancer.

Authors:  Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03       Impact factor: 9.236

8.  Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Authors:  Hannah M Linden; Brenda F Kurland; Lanell M Peterson; Erin K Schubert; Julie R Gralow; Jennifer M Specht; Georgiana K Ellis; Thomas J Lawton; Robert B Livingston; Philip H Petra; Jeanne M Link; Kenneth A Krohn; David A Mankoff
Journal:  Clin Cancer Res       Date:  2011-07-12       Impact factor: 12.531

Review 9.  Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.

Authors:  Austin R Pantel; David A Mankoff
Journal:  Cancer Lett       Date:  2016-05-16       Impact factor: 8.679

Review 10.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.